Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

EssilorLuxottica Reports 6-Month Clinical Trial Results for Stellest 2.0 Lenses

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

China

◆ Source

Read at eyewire.news →

◆ Verified

Fusion42 · 22 September 2026 · Fusion42 review

EssilorLuxottica's ongoing 6-month clinical trial in China shows Stellest 2.0 lenses effectively slow myopia progression and axial elongation in children compared to single-vision lenses, with high compliance and adaptation rates.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now offer faster-acting myopia control with Stellest 2.0 lenses proven to slow progression within 6 months. This opens a door to capture pediatric eye care patients seeking effective vision solutions.

◆ Coverage

1 source · 22 Sep 2026

◆ Related on Wire

◆ Topics

Medtechmyopiaclinical-trialeyewearchild-healthvision-correction